Zenith National Insurance Corp. and Subsidiaries

Consolidated Financial Statements as of March 31, 2024 and December 31, 2023 and for the three months ended March 31, 2024 and 2023 (unaudited)

Zenith National Insurance Corp. and Subsidiaries Consolidated Financial Statements (unaudited)

Table of Contents

	<u>Page</u>
Consolidated Balance Sheets – March 31, 2024 and December 31, 2023	3
Consolidated Statements of Comprehensive Income (Loss) – Three Months Ended March 31, 2024 and 2023	4
Consolidated Statements of Cash Flows – Three Months Ended March 31, 2024 and 2023	5
Consolidated Statements of Stockholders' Equity – Three Months Ended March 31, 2024 and 2023	7
Notes to Consolidated Financial Statements	8

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except par value)		March 31, 2024	December 31 2023		
Assets:		2024		2023	
Investments:					
Fixed maturity securities, at fair value (amortized cost \$935,941 in 2024 and \$1,030,941 in 2023)	\$	944,384	\$	1,052,865	
Equity securities, at fair value (cost \$273,400 in 2024 and \$273,401 in 2023)	*	296,038	*	312,725	
Short-term investments, at fair value which approximates cost		10,568		7,550	
Mortgage loans, at fair value (amortized cost \$221,618 in 2024 and \$218,523 in 2023)		213,953		210,758	
Other investments		218,235		213,447	
Derivative assets, at fair value (cost \$15,035 in 2024 and \$17,835 in 2023)		759		2,551	
Total investments		1,683,937		1,799,896	
Cash and cash equivalents		41,519		39,060	
Accrued investment income		9,820		11,958	
Premiums receivable		73,307		64,982	
Earned but unbilled premium receivable		5,218		5,218	
Reinsurance recoverables		53,971		49,541	
Deferred policy acquisition costs		25,160		23,087	
Deferred tax asset		74,808		65,887	
Operating lease right-of-use assets		22,545		23,799	
Goodwill		20,985		20,985	
Other assets		52,599		59,025	
Total assets	\$	2,063,869	\$	2,163,438	
Liabilities:					
Unpaid losses and loss adjustment expenses	\$	1,043,642	¢	1,045,700	
Unearned premiums	Ψ	141,235	Ψ	129,080	
Policyholders' dividends accrued		31,790		31,848	
Long-term debt		38,375		38,368	
Income tax payable		5,925		704	
Operating lease liabilities		24,179		25,329	
Derivative liabilities		65		2,276	
Other liabilities		103,018		100,214	
Total liabilities		1,388,229		1,373,519	
Commitments and contingencies (see Note 9)					
Stockholders' equity:					
Common stock, \$1 par value, 40 authorized shares; 39 shares issued and outstanding		39		39	
Additional paid-in capital		400,566		401,199	
Retained earnings		292,211		406,673	
Accumulated other comprehensive loss		(17,176)		(17,992)	
Total stockholders' equity		675,640		789,919	
Total liabilities and stockholders' equity	\$	2,063,869	\$	2,163,438	

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

	Thr	Three Months Ended March 31,				
(In thousands)		2024	2023			
Revenues:						
Net premiums earned	\$	178,349 \$	175,518			
Net investment income		13,889	14,751			
Net realized gain (loss) on investments		(1,599)	111,955			
Change in net unrealized gains/losses on fair value option investments		(30,936)	(80,218			
Net gain (loss) on derivatives		791	(128			
Service fee revenue		2,767	2,120			
Total revenues		163,261	223,998			
Expenses:						
Losses and loss adjustment expenses incurred		101,086	102,510			
Underwriting and other operating expenses:						
Policyholder acquisition costs		40,536	37,701			
Underwriting and other costs		34,775	32,182			
Policyholders' dividends		4,177	4,906			
Interest expense		830	830			
Total expenses		181,404	178,129			
Income (loss) before tax		(18,143)	45,869			
Income tax expense (benefit)		(3,681)	10,798			
Net income (loss)	\$	(14,462) \$	35,071			
Change in unrealized gains/losses on investments, net of tax		284	214			
Change in unrealized foreign currency translation adjustments, net of tax		532	(359			
Other comprehensive income (loss)		816	(145			
Total comprehensive income (loss)	\$	(13,646) \$	34,926			

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Th	Three Months Ended March 31,				
(In thousands)		2024				
Cash flows from operating activities:						
Premiums collected, net of reinsurance	\$	182,099 \$	178,506			
Investment income received	•	13,501	5,177			
Losses and loss adjustment expenses paid, net of reinsurance		(104,265)	(116,104			
Underwriting and other operating expenses paid		(69,846)	(71,373			
Interest paid		(1,646)	(1,646			
Income taxes paid		(237)	(5,411			
Net cash provided by (used in) operating activities		19,606	(10,851			
Cash flows from investing activities:						
Purchases of investments:		(0.40)	(074.044			
Fixed maturity securities - fair value option		(640)	(271,211			
Equity securities - fair value option		(0.405)	(26,452			
Mortgage loans		(3,435)	(915			
Other investments		(8,326)	(9,121			
Proceeds from maturities and redemptions of investments:		7.404	45.454			
Fixed maturity securities - fair value option		7,464	15,151			
Proceeds from sales of investments:						
Fixed maturity securities - fair value option		88,954	146,928			
Equity securities - fair value option			169,841			
Mortgage loans		933	73			
Other investments		1,565	2,396			
Net increase in short-term investments		(1,333)	(11,658			
Net derivative cash settlements		372	199			
Capital expenditures and other		(599)	(2,678			
Net cash provided by investing activities		84,955	12,553			
Coch flows from financing activities:						
Cash flows from financing activities:		(100,000)				
Dividends paid to common stockholders		(100,000)	(447			
Purchase of Fairfax shares for restricted stock awards		(2,102)	(117			
Net cash used in financing activities		(102,102)	(117			
Net increase in cash and cash equivalents		2,459	1,585			
Cash and cash equivalents at beginning of period		39,060	37,736			
Cash and cash equivalents at end of period	\$	41,519 \$	39,321			

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (UNAUDITED)

	Th	Three Months Ended March 31,			
(In thousands)		2024	2023		
Reconciliation of net income (loss) to net cash provided by (used in operating activities:)				
Net income (loss)	\$	(14,462) \$	35,07		
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation expense		317	469		
Net accretion		(2,944)	(2,610		
Net realized loss (gain) on investments		1,599	(111,95		
Change in net unrealized losses on fair value option investments		30,936	80,21		
Net loss (gain) on derivatives		(791)	12		
Equity in losses (earnings) of investee		2,379	(3,36		
Stock-based compensation expense		1,469	1,45		
Decrease (increase) in:					
Accrued investment income		2,138	(2,65		
Premiums receivable		(10,445)	(8,61		
Reinsurance recoverables		(4,430)	46		
Deferred policy acquisition costs		(2,073)	(1,73		
Net income taxes		(3,918)	5,38		
Increase (decrease) in:					
Unpaid losses and loss adjustment expenses		(2,058)	(15,14		
Unearned premiums		12,155	11,92		
Policyholders' dividends accrued		(58)	65		
Accrued expenses		3,786	(6,12		
Interest payable		(823)	(82		
Prepaid policy and guarantee fund assessments		5,221	4,47		
Other		1,608	1,92		
Net cash provided by (used in) operating activities	\$	19,606 \$	(10,85		

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

	7	Three Months Ende	d March 31,
(In thousands)		2024	2023
Common stock:	\$	39 \$	39
Additional paid-in capital:			
Beginning of period		401,199	397,682
Stock-based compensation expense		1,469	1,454
Purchases of Fairfax shares for restricted stock awards		(2,102)	(117)
End of period		400,566	399,019
Retained earnings:			
Beginning of period		406,673	318,733
Net income (loss)		(14,462)	35,071
Dividends to common stockholders		(100,000)	
End of period		292,211	353,804
Accumulated other comprehensive loss:			
Beginning of period		(17,992)	(11,848)
Change in unrealized gains/losses on investments, net of tax		284	214
Change in unrealized foreign currency translation adjustments, net of tax		532	(359)
End of period		(17,176)	(11,993)
Total stockholders' equity	\$	675,640 \$	740,869

Note 1. Basis of Presentation and Accounting Policies

Basis of Presentation

Zenith National Insurance Corp. ("Zenith National") is a Delaware holding company, which is a wholly-owned indirect subsidiary of Fairfax Financial Holdings Limited ("Fairfax"). Fairfax is a Canadian financial services holding company, whose common stock is publicly traded on the Toronto Stock Exchange, and is principally engaged in property and casualty insurance, reinsurance and associated investment management. Zenith National's wholly-owned subsidiaries (primarily Zenith Insurance Company ("Zenith Insurance")), specialize in the workers' compensation insurance business, nationally and, since 2010, in the property-casualty business for California agriculture. Unless otherwise indicated, all references to the "Company" refer to Zenith National together with its subsidiaries.

The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including normal, recurring adjustments) necessary for a fair presentation of the Company's financial position and results of operations for the periods presented have been included. The results of operations for an interim period are not necessarily indicative of the results for an entire year. These Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and Notes thereto of the Company for the year ended December 31, 2023.

Adopted Accounting Standards

Measurement of Credit Losses on Financial Instruments

Effective January 1, 2023, the Company adopted the new guidance on Financial Instruments – Credit Losses, which provides for the recognition and measurement of all expected credit losses ("CECL") for financial assets that are not recorded under the fair value option method of accounting. The adoption involved reassessing credit losses on the Company's financial assets that are not accounted for at fair value, following the prescribed methodology for recognizing credit losses that reflects expected credit losses. The Company's investment portfolio, excluding accrued investment income, was not affected by CECL as it applies the fair value option to the majority of its investments. Therefore, the Company's financial assets within the scope of this guidance primarily included accrued investment income, premiums receivable and reinsurance recoverable. Following the adoption of CECL, the Company reassesses credit losses on its financial assets within the scope of the guidance quarterly. The adoption of this guidance did not result in any additional credit losses recorded on the Company's significant financial assets in scope

Recent Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions

In June 2022, the Financial Accounting Standards Board issued new guidance which clarifies the existing fair value measurement guidance, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The new standard clarifies that a contractual restriction on the sale of an equity security that are characteristics of the equity security should be considered in measuring the fair value of the security. The standard also requires an entity holding equity securities with contractual sale restrictions to disclose the fair value of equity securities subject to contractual sale restrictions, the nature and remaining duration of the restrictions and the circumstances that could cause a lapse in the restrictions. For non-public entities, the guidance is effective for annual periods beginning after December 15, 2024 and interim periods within those annual periods. Early adoption is permitted. The guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations, or cash flows.

Improvements to Income Tax Disclosures

In December 2023, the FASB issued new guidance requiring expanded income tax disclosures, including the disaggregation of existing disclosures related to the effective tax rate reconciliation and income taxes

paid. For non-public entities, the guidance is effective for annual periods beginning after December 15, 2025. Prospective application is required, with retrospective application permitted. The guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations, or cash flows.

Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements have been reclassified and amended to conform to the current year presentation.

Subsequent Events

The Company evaluated subsequent events through the date and time that the Consolidated Financial Statements were issued on May 15, 2024.

Note 2. Cash and Investments

In April 2023, the Company started investing substantially all of its operating cash balances in a highly liquid overnight money market fund, administered by Bank of America through a daily sweep mechanism. Previously, the Company held all of its operating cash in cash accounts at Bank of America. The invested balance as of March 31, 2024 was \$28.0 million and was included as part of net cash and cash equivalents on the Consolidated Balance Sheets.

The cost or amortized cost and fair value of investments recorded at fair value under the fair value option as of March 31, 2024 and December 31, 2023 were as follows:

	Co	ost or Amortized		Gross Unre	Fair	
(In thousands)		Cost			(Losses)	Value (a)
March 31, 2024						
Fair value option investments:						
Fixed maturity securities:						
U.S. Government debt	\$	872,962	\$	5,762 \$	(3,021) \$	875,703
Foreign government debt		15,952		703		16,655
Corporate debt		47,027		5,157	(158)	52,026
Total fixed maturity securities		935,941		11,622	(3,179)	944,384
Equity securities		273,400		60,946	(38,308)	296,038
Short-term investments		10,568				10,568
Mortgage loans		221,618			(7,665)	213,953
Cost-method partnerships		46,115		11,276	(2,286)	55,105
Affiliate corporate loans		7,090		8		7,098
Contingent consideration receivable		23,525			(1,132)	22,393
Total fair value option investments	\$	1,518,257	\$	83,852 \$	(52,570) \$	1,549,539
December 31, 2023						
Fair value option investments:						
Fixed maturity securities:						
U.S. Government debt	\$	968,488	\$	18,203 \$	(2,633) \$	984,058
Foreign government debt		15,915		566		16,481
Corporate debt		46,538		5,941	(153)	52,326
Total fixed maturity securities		1,030,941		24,710	(2,786)	1,052,865
Equity securities		273,401		80,648	(41,324)	312,725
Short-term investments		7,550				7,550
Mortgage loans		218,523			(7,765)	210,758
Cost-method partnerships		38,283		10,900	(2,313)	46,870
Affiliate corporate loans		7,091		119		7,210
Contingent consideration receivable		23,525		29		23,554
Total fair value option investments	\$	1,599,314	\$	116,406 \$	(54,188) \$	1,661,532

⁽a) For additional disclosures regarding methods and assumptions used in estimating fair values, see Note 4.

Fixed maturity securities, including short-term investments, by contractual maturity as of March 31, 2024 were as follows:

	Fair
(In thousands)	Value
Due in one year or less	\$ 25,069
Due after one year through five years	529,059
Due after five years through ten years	400,824
Total	\$ 954,952

Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

As of March 31, 2024 and December 31, 2023, total investments also included other investments detailed below and derivative contracts described in Note 3.

(In thousands)	March 31, 2024	Dec	cember 31, 2023
Equity-method common stock (a)	\$ 133,639	\$	135,813
Cost-method partnerships, at fair value (cost \$46,115 in 2024 and \$38,283 in 2023) (b)	55,105		46,870
Affiliate corporate loans, at fair value (amortized cost \$7,090 in 2024 and \$7,091 in 2023)	7,098		7,210
Contingent consideration receivable, at fair value (cost \$23,525 in 2024 and 2023)	22,393		23,554
Total other investments	\$ 218,235	\$	213,447

⁽a) Investments in equity-method common stock are recorded at cost, adjusted for subsequent purchases, distributions, other-than-temporary impairments, if any, and the Company's share of the changes in the investee's equity since the initial acquisition.

As of March 31, 2024, the Company had commitments to invest an additional \$9.4 million in partnerships and limited liability companies.

The following table sets forth additional information for the Company's investment in equity-method common stock as of March 31, 2024 and December 31, 2023:

		Carryi	ng ∨	⁄a ue				Carrying Value less Underlying Net Asset Value						Quoted Market Value		Relative Economic Ownership	
	N	larch 31,	De	cember 31,	V	larch 31,		Decembe	er 31,		March 31,	D	ecember 31,	March 31,			
(In thousands)		2024		2023		2024		2023		2023		2023			2023	2024	
FF Meadow Holdings Limited	\$	50,428	\$	50,428										20.3 %			
Fairfax India Holdings Corp.		30,271		28,928	\$	(600)	(a)	\$	(579)	(a)	\$ 21,008	\$	21,474	1.0 %			
Grivalia Hospitality S.A.		12,330		12,349		6,228	(a)	5	5,988	(a)				1.8 %			
Exco Resources Inc.		11,081		10,175		(1,085)	(a)		(578)	(a)				1.3 %			
Peak Achievement Athletics		8,646		8,614				(*	,204)	(c)				2.8 %			
Helios Fairfax Partners Corp.		7,105		10,466		(13,139)	(b)	(13	3,130)	(b)	12,504		11,074	4.3 %			
Astarta Holdings NV		6,421		6,421		(7,299)	(b)	(7	7,299)	(b)	5,929	1	5,900	3.3 %			
Alberta ULC		4,084		3,658										5.0 %			
Boat Rocker Media Inc.		3,273		4,774		(9,050)	(b)	3)	3,035)	(b)	3,273	,	4,774	8.9 %			
Total common stocks, at equity	\$	133,639	\$	135,813													

⁽a) Represents positive/(negative) goodwill.

⁽b) Investments in partnerships and limited liability companies where the Company's ownership is minor and the Company does not have significant operating or financial influence are recorded at fair value.

⁽b) Represents primarily other-than-temporary impairment write-down previously recorded.

⁽c) Represents dividend distribution received from investee not yet reflected in the underlying net asset value ("NAV") based on the most recent investee financial statements received.

Net investment income was as follows:

	Three Months Ended March					
(In thousands)		2024	2023			
Fixed maturity securities (a)	\$	11,068 \$	7,004			
Equity securities		1,540	2,031			
Mortgage loans (a)		5,193	3,535			
Short-term and other investments (a)		900	984			
Net income (loss) from equity-method investment (b)		(2,379)	3,365			
Subtotal		16,322	16,919			
Less: Investment expenses		2,433	2,168			
Net investment income	\$	13,889 \$	14,751			

- (a) During the year ended December 31, 2023, the Company continued to reinvest proceeds from sales and maturities of short-dated fixed maturity securities into higher yielding U.S. treasury bonds, high quality corporate bonds and first mortgage loans, resulting in a higher interest income in the three months ended March 31, 2024.
- (b) Income (loss) from equity-method investments for each period presented is detailed below:

	Three Months Ended March 31,					
n thousands)		2024	2023			
Fairfax India Holdings Corp.	\$	1,408 \$	946			
Exco Resources Inc.		906	1,781			
Alberta ULC		326	22			
Peak Achievement Athletics		16	(58)			
Boat Rocker Media Inc.		(729)	189			
Grivalia Hospitality		(855)	(8)			
Helios Fairfax Partners Corp.		(3,451)	748			
Farmers Edge Inc. (1)			(255)			
Income (loss) from equity-method investments	\$	(2,379) \$	3,365			

⁽¹⁾ As of March 31, 2024, based on the Farmers Edge Inc. ("FE") latest GAAP financial statements as of December 31, 2022 (audited) received and International Financial Reporting Standards ("IFRS") financial statements as of December 31, 2023 (unaudited), the Company's remaining share of the FE's reduction in equity not yet recognized in the Company's results was approximately \$2.0 million.

Net realized gains (losses) on investments, excluding derivatives, were as follows:

	Т	hree Months Ende	d March 31,
(In thousands)		2024	2023
Sales of equity securities (a)		\$	113,231
Sales of fixed maturity securities, including short-term investments and other (b)	\$	(1,843)	(1,998)
Gain from other investments		244	722
Net realized gain (loss) on investments	\$	(1,599) \$	111,955

- (a) Net realized gain on sales of equity securities in the three months ended March 31, 2023 primarily consisted of \$113.2 million of a realized gain on sale of a common stock investment, \$110.5 million of which was previously recorded in change in net unrealized gains/losses on fair value option investments (see tickmark (a) in the table below).
- (b) Net realized losses on sales of fixed maturity securities, including short-term investments and other in the three months ended March 31, 2024 primarily included realized losses from sales of U.S. government securities of \$1.8 million.

Net realized losses on sales of fixed maturity securities, including short-term investments and other in the three months ended March 31, 2023 primarily included realized losses on sale of U.S. government securities of \$2.7 million, partially offset by an additional realized gain of \$0.9 million related to the acquisition of Apple Bidco Limited ("AB") in 2020 by Atlas Corp.'s ("Atlas", formerly Seaspan Corporation, or "Seaspan"), both affiliates of Fairfax and the Company.

The change in net unrealized gains/losses on fair value option investments still held was as follows:

	Т	Three Months Ended March 31,					
(In thousands)		2024	2023				
Change in net unrealized gains/losses recognized on fair value option investments	\$	(30,936) \$	(80,218)				
Less: Net loss (gain) recognized on fair value option investments sold (a)		1,046	(109,291)				
Change in net unrealized gains/losses recognized on fair value option investments still held at the reporting date	\$	(31,982) \$	29,073				

⁽a) Net gain recognized on fair value option investments sold primarily in the three months ended March 31, 2023 consisted of \$110.5 million cumulative unrealized gains previously recognized through December 31, 2022 on a common stock investment sold in the first quarter of 2023 (see tickmark (a) in the table above).

As of March 31, 2024 and December 31, 2023, investments with a fair value of approximately \$770 million, were on deposit with regulatory authorities in compliance with insurance company regulations. As of March 31, 2024, the Company had additional qualifying securities with a fair value of approximately \$130 million available for deposit.

Note 3. Derivative Contracts

Derivatives entered into by the Company are considered investments or economic hedges and are not designated for hedge accounting treatment for financial reporting. Derivatives are carried at fair value. The fair value of derivatives in a gain position and fair value of derivatives in a loss position are presented as derivative assets and derivative liabilities, respectively, in the Consolidated Balance Sheets. The initial premium paid for a derivative contract, if any, is recorded as a derivative asset and subsequently adjusted for changes in the fair value of the contract at each reporting date. Changes in the fair value of derivatives are recorded as net gains (losses) on derivatives in the Consolidated Statements of Comprehensive Income (Loss), with a corresponding adjustment to the carrying value of the derivative asset or liability. Cash settlements related to fair value changes on derivatives are also recorded in the Consolidated Statements of Comprehensive Income (Loss) as net gains (losses) on derivatives, and are recorded as an investing activity in the Consolidated Statements of Cash Flows.

Cash received from counterparties as collateral for derivative contracts is recorded as other assets with a corresponding liability recorded in other liabilities in the Consolidated Balance Sheets. Securities pledged by counterparties to the Company as collateral for derivatives in a gain position are not recorded as assets. Securities pledged by the Company as collateral to counterparties for derivative contracts in a loss position, as well as contractually required independent collateral, are recorded in assets pledged for derivative obligations in the Consolidated Balance Sheets.

The following table summarizes the notional amounts, cost and fair values of derivative contracts:

	Notional		Fair Value of Derivative					
(In thousands)	Amount	Cost		Assets		Liabilities		
March 31, 2024								
CPI-linked derivatives	\$ 2,069,473	\$ 8,391						
Equity index put options	124,358	4,821	\$	519				
Foreign exchange forwards	104,902			182	\$	65		
Equity warrants	10,000	1,823		58				
Total		\$ 15,035	\$	759	\$	65		
December 31, 2023								
CPI-linked derivatives	\$ 3,082,328	\$ 11,191						
Equity index put options	124,358	4,821	\$	2,121				
Foreign exchange forwards	100,951				\$	2,276		
Equity warrants	10,000	1,823		430				
Total		\$ 17,835	\$	2,551	\$	2,276		

The gains (losses) from settlements and changes in fair value of the derivative contracts were recorded in net gains (losses) on derivatives in the Consolidated Statements of Comprehensive Income (Loss) and were as follows:

	Three Months Ende	d March 31,
(In thousands)	 2024	2023
Net gains (losses) on settlements		
Equity warrants	\$	1,367
CPI-linked derivatives	\$ (2,800)	(799)
Foreign exchange forwards	372	198
Total	(2,428)	766
Change in fair value		
Equity warrants	(372)	(1,317)
Equity index put options	(1,602)	
CPI-linked derivatives	2,800	799
Foreign exchange forwards	2,393	(376)
Total	3,219	(894)
Net gain (loss) on derivatives		
Equity warrants	(372)	50
Equity index put options	(1,602)	
Foreign exchange forwards	2,765	(178)
Total net gain (loss) on derivatives	\$ 791 \$	(128)

As of March 31, 2024 and December 31, 2023, counterparties pledged \$0.6 million of U.S Treasury notes and \$2.1 million of cash, respectively, for the Company's benefit. The Company recorded the cash collateral in other assets and recorded a corresponding liability in its Consolidated Balance Sheets.

Note 4. Fair Value Measurements

Fair values for substantially all of the Company's financial instruments are measured using market or income approaches. Considerable judgment may be required in interpreting market data used to develop estimates of fair value. Accordingly, actual values realized in future market transactions may differ from the estimates presented in these consolidated financial statements. In determining fair value, the Company primarily uses prices and other relevant information generated by market transactions involving identical or comparable assets ("market approach"). The Company also considers the impact of a significant decrease in volume and level of activity for an asset or liability when compared with normal activity to identify transactions that are not orderly.

Fair value measurements are determined under a three level hierarchy that prioritizes the inputs to valuation techniques used to measure fair value, distinguishing between market participant assumptions developed based on market data obtained from sources independent of the reporting entity ("observable inputs") and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances ("unobservable inputs"). The hierarchy level assigned to each security carried at fair value is based on the Company's assessment of the transparency and reliability of the inputs used in the valuation of each instrument at the measurement date. The highest priority is given to unadjusted quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Securities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company recognizes transfers between levels at the end of each reporting period in which the transfer is identified.

The three hierarchy levels are defined as follows:

Level 1— Inputs represent unadjusted quoted prices for identical instruments exchanged in active markets. The fair values of publicly traded equity securities, highly liquid cash management funds and short-term U.S. Government securities are based on published quotes in active markets.

Level 2— Inputs include directly or indirectly observable inputs (other than Level 1 inputs) such as quoted prices for similar financial instruments exchanged in active markets, quoted prices for identical or similar financial instruments exchanged in inactive markets and other market observable inputs. The fair value of the vast majority of the Company's investments in fixed maturity securities, along with most derivative contracts are priced based on information provided by independent pricing service providers, while much of the remainder are based primarily on non-binding third party broker-dealer quotes that are prepared using Level 2 inputs. Where third party broker-dealer quotes are used, typically at least one quote is obtained from a broker-dealer with particular expertise in the instrument being priced. Certain common stock investments, which are measured at fair value using the NAV as a practical expedient, have been excluded.

Level 3— Inputs include unobservable inputs used in the measurement of financial instruments. Management is required to use its own assumptions regarding unobservable inputs, as there is little, if any, market activity in these instruments or related observable inputs that can be corroborated at the measurement date. Certain cost-method partnership investments, which are measured at fair value using the NAV practical expedient, have been excluded. Investments for which NAV is only a component of the fair value measurement continue to be included.

The following table presents the Company's investments measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 classified by the valuation hierarchy discussed previously:

				Fair V	Value Measurement Using					
(In thousands)		Total (a)		Level 1		Level 2		Level 3		
March 31, 2024										
Fair value option securities:										
Fixed maturity securities:										
U.S. government debt	\$	875,703			\$	875,703				
Foreign government debt		16,655				16,655				
Corporate debt		52,026				42,380	\$	9,646		
Total fixed maturity securities		944,384				934,738		9,646		
Equity securities (a) (b)		296,038	\$	144,837		9,803		111,648		
Short-term investments		10,568		10,568						
Mortgage loans		213,953						213,953		
Other investments – cost-method partnerships (a) (b)		55,105								
Other investments – affiliate corporate loans (a)		7,098						7,098		
Other investments – contingent consideration receivable (a)		22,393						22,393		
Total fair value option investments	\$	1,549,539	\$	155,405	\$	944,541	\$	364,738		
Derivatives:										
Equity warrants	\$	58					\$	58		
Equity index put options		519			\$	519				
Foreign exchange forwards		182				182				
Total derivative assets		759				701		58		
Foreign exchange forwards		(65)				(65)				
Total derivative liabilities		(65)				(65)				
Net derivatives	\$	694			\$	636	\$	58		

				Fair V	Value Measurement Using					
(In thousands)		Total (a)		Level 1		Level 2		Level 3		
December 31, 2023										
Fair value option securities:										
Fixed maturity securities:										
U.S. government debt	\$	984,058			\$	984,058				
Foreign government debt		16,481				16,481				
Corporate debt		52,326				42,191	\$	10,135		
Total fixed maturity securities		1,052,865				1,042,730		10,135		
Equity securities (a) (b)		312,725	\$	162,034		9,555		112,787		
Short-term investments		7,550		7,550						
Mortgage loans		210,758						210,758		
Other investments – cost-method partnerships (a) (b)		46,870								
Other investments – affiliate corporate loans (a)		7,210						7,210		
Other investments – contingent consideration receivable (a)		23,554						23,554		
Total fair value option investments	\$	1,661,532	\$	169,584	\$	1,052,285	\$	364,444		
Derivatives:										
Equity warrants	\$	430					\$	430		
Equity index put options		2,121			\$	2,121				
Total derivative assets		2,551				2,121		430		
Foreign exchange forwards		(2,276)				(2,276)				
Total derivative liabilities		(2,276)				(2,276)				
Net derivatives	\$	275			\$	(155)	\$	430		

⁽a) The fair value amounts presented in the "Total" column are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets. Cost-method partnerships, affiliate corporate loans and contingent consideration receivable are part of the composition of other investments in the Consolidated Balance Sheets. See Note 2 for additional details of investments recorded under other investments.

⁽b) As of March 31, 2024 and December 31, 2023, certain common stock investments with a fair value of \$29.7 million and \$28.3 million, respectively, and cost-method partnerships with a fair value of \$55.1 million and \$46.9 million, respectively, are measured using NAV as a practical expedient and are not required to be classified in the fair value hierarchy.

The following table presents changes in the Company's Level 3 fixed maturity and equity securities, mortgage loans, affiliate corporate loans, contingent consideration receivable and derivatives measured at fair value on a recurring basis:

(In thousands)	C	Corporate Debt	S	Equity ecurities (a)	М	lortgage Loans	Affiliate Corporate Loans	С	Contingent onsideration eceivable (b)	De	rivatives
Balance as of December 31, 2023	\$	10,135	\$	112,787	\$	210,758	\$ 7,210	\$	23,554	\$	430
Purchases						4,022					
Sales						(1,173)					
Realized and unrealized gains/losses included in:											
Net investment income – accretion of discounts						246					
Change in net unrealized gains/losses on fair value option investments		(489))	(1,139))	100	(112)		(1,161)		
Net loss on derivatives											(372)
Balance as of March 31, 2024	\$	9,646	\$	111,648	\$	213,953	\$ 7,098	\$	22,393	\$	58
Balance as of December 31, 2022	\$	2,124	\$	38,921	\$	162,019	\$ 8,913	\$	15,723	\$	1,879
Purchases		5,339		4,000		1,020			11,759		
Sales						(73)			(1,192)		(1,500)
Realized and unrealized gains/losses included in:											
Net investment income – accretion of discounts						(20)					
Net realized loss on investments									(63)		
Change in net unrealized gains/losses on fair value option investments		2,297		897			270		1,164		
Net gain on derivatives											50
Balance as of March 31, 2023	\$	9,760	\$	43,818	\$	162,946	\$ 9,183	\$	27,391	\$	429

⁽a) Change in unrealized gains/losses for equity securities included change in fair value and foreign currency fluctuation.

⁽b) Purchase of Contingent Consideration Receivables in 2023 of \$11.8 million represents the fair value of contingent value rights ("CVR") recorded as a result of a sale of a common stock investment in the first quarter of 2023. The fair value of the CVR was estimated as the difference between cash consideration received and the market price of the common stock immediately prior to the close of the transaction, and was included as part of total sales proceeds.

Note 5. Related Party Transactions

Investments

Management of all of the Company's investments is centralized at Fairfax through investment management agreements entered into in 2010. The parties to these agreements are Zenith National's insurance subsidiaries, Fairfax and Hamblin Watsa Investment Counsel, Ltd. ("HWIC"), an affiliate of Fairfax and the Company. In the three months ended March 31, 2024 and 2023, investment management expenses incurred under these agreements were \$1.3 million.

The Company owns fixed maturity securities, common stock, preferred stock and corporate loans issued by public and private companies and invests in limited partnerships which are affiliates of Fairfax and the Company (including but not limited to investments described in the following paragraphs). Affiliated common stock investments are recorded using the equity-method of accounting, unless the fair value option is elected. The Company's share of an equity-method investee's net income (loss) and net realized gains (losses) from sales and share dilutions are recorded in net investment income (loss) and net realized gains (losses) from investments, respectively, in the Consolidated Statements of Comprehensive Income (Loss). The Company's share of an equity-method investee's other changes in equity and net unrealized gains (losses) on foreign currency translation adjustments are recorded in the change in unrealized gains/losses on investments and change in unrealized foreign currency translation adjustments, respectively, in other comprehensive income (loss).

The Company's affiliated investments as of March 31, 2024 and December 31, 2023 were as follows:

	March 31,	December 31,
(In thousands)	2024	2023
Equity securities, at fair value	\$ 195,013	\$ 204,272
Other investments:		
Equity-method common stock	133,639	135,813
Partnerships, at fair value	5,629	5,661
Affiliate corporate loans, at fair value	7,098	7,210
Total affiliated investment assets	\$ 341,379	\$ 352,956
Other liabilities – indemnity liability resulting from the sale of AB to Atlas	\$ (12,541)	\$ (12,541)

The following table summarizes the impact from the Company's affiliated investments on various components of total comprehensive income (loss):

	Three Months Ended March 31,						
(In thousands)	2024	2023					
Included in net income (loss), before tax							
Net investment income (loss)	\$ (966) \$	5,104					
Net realized gain (loss) on investments	(589)	1,884					
Change in net unrealized gains/losses on fair value option investments	(9,484)	12,814					
Net loss on derivatives		(1,390)					
Included in other comprehensive income (loss), before tax:							
Change in unrealized gains/losses on investments, before tax	359	270					
Change in unrealized foreign currency translation adjustments, before tax	674	(454)					
Included in total comprehensive income (loss), before tax:	\$ (10,006) \$	18,228					

On October 27, 2023, Fairfax, through its subsidiaries, including the Company, made a \$750 million commitment to Waterous Energy Fund III (International FI) LP ("Waterous LP"), an oil and gas limited partnership located in Calgary, Canada. The Company's share of the commitment is \$4.0 million, and it contributed \$0.1 million to the fund in January 2024. Fairfax concluded to have significant influence over Waterous LP; therefore, it became an affiliate of Fairfax and the Company simultaneous with this investment. The Company elected fair value option accounting for its investment in Waterous LP, and the carrying value of this investment was \$0.1 million as of March 31, 2024.

On March 21, 2024, Fairfax, through its subsidiaries, completed privatization of FE, an affiliate of Fairfax and the Company, and acquired all the outstanding common shares of FE not previously held by Fairfax and its subsidiaries for a price of CAD \$0.35 per share. FE's common stock was delisted from the Toronto Stock Exchange at the close of trading on March 25, 2024. As of March 31, 2024 and December 31, 2023, the carrying value of the Company's equity-method investment in FE common stock was zero.

In March 2024, the Company recorded an additional other-than-temporary impairment of \$1.0 million for the equity-accounted Boat Rocker affiliated common stock as a result of continuous decline in the traded value of Boat Rocker shares. As of March 31, 2024 and December 31, 2023, the carrying value of the Company's equity-method investment in Boat Rocker common stock was \$3.3 million and \$4.8 million, respectively.

On March 31, 2023, Fairfax finalized an agreement with ONX Inc. ("ONX") to purchase debentures, warrants and additional preferred shares resulting in an increase to Fairfax's ownership and board representation. Thus, Fairfax concluded that it had significant influence over ONX, and ONX became an affiliate of Fairfax and the Company. The Company's share of this investment was \$9.0 million in preferred stock and \$0.5 million in common stock of ONX, and the Company elected the fair value option of accounting for these investments. As of both March 31, 2024 and December 31, 2023, the carrying values of the Company's investments in ONX preferred and common stock were \$9.0 million and \$0.5 million, respectively.

In March 2023, the Company purchased an additional 3.1 million common stock shares in Grivalia Hospitality S.A. ("GH"), an affiliate of Fairfax and the Company for \$5.4 million. In July 2022, Fairfax through its subsidiaries, including the Company, increased its interest in GH by acquiring additional common stock shares and commenced consolidating GH in the third quarter of 2022. The Company's share of this additional investment was \$7.1 million. The Company continues to account for its investment in GH affiliated common stock using the equity-method of accounting. As of March 31, 2024 and December 31, 2023, the carrying value of the Company's investment in GH affiliated common stock was \$12.3 million.

On March 28, 2023, Atlas and Poseidon Acquisition Corp. ("PAC") announced the completion of the acquisition by PAC of all outstanding common shares of Atlas not already owned by Fairfax and other Poseidon investors ("Poseidon Merger"). PAC was a consortium formed by Fairfax and other investors to complete the Poseidon Merger. Surviving entity has been renamed Poseidon.

In January 2023, in connection with the Poseidon Merger, the Company exercised its Atlas common stock warrants for a cash payment of \$8.5 million, in exchange for 0.7 million of Atlas common stock shares, recorded at a cost of \$10.0 million. Separately, on March 9, 2023, Fairfax, including the Company, received additional Atlas common stock shares that were previously held back at the time of the closing of the sale transaction of APR Energy (known as AB, an affiliated investment of both Fairfax and the Company) to Atlas on February 28, 2020. The Company recorded its portion of Atlas common stock shares received at cost of \$0.9 million, with an offset recorded in realized gain – other (effectively recognizing additional realized gain on the sale of APR Energy to Atlas). As of March 31, 2024 and December 31, 2023, the carrying value of the Company's fair value option investment in Poseidon (formerly Atlas) common stock was \$55.9 million. The Company also owns preferred stock issued by Atlas, with the carrying value of \$9.8 million and \$9.6 million as of March 31, 2024 and December 31, 2023, respectively.

Other

In the three months ended March 31, 2024, Zenith National paid ordinary cash dividends of \$100.0 million to affiliates of Fairfax and the Company. No dividends were paid in the three months ended March 31, 2023.

In the three months ended March 31, 2024, Zenith Insurance paid ordinary cash dividends of \$105.0 million to Zenith National. Zenith Insurance has the ability to pay up to \$100.3 million of additional dividends to Zenith National without prior approval of the California Department of Insurance ("California DOI") during the

remainder of 2024. No dividends were paid in the three months ended March 31, 2023.

The Company continues to be a party to the reinsurance agreements with various subsidiaries of Allied World Assurance Company Holdings, Ltd. (collectively "Allied"), an affiliate of Fairfax and the Company for 2021 through 2024. The following table summarizes the significant impact from these agreements on various components of the balance sheet:

		March 31,	December 31,		
(In thousands)		2024	2023		
Assets:					
Premiums receivable	\$	8,572	\$ 9,082		
Deferred policy acquisition costs		6,611	7,156		
Liabilities:					
Unpaid losses and loss adjustment expenses		46,621	41,945		
Unearned premiums		18,234	19,791		

The following table summarizes the significant impact from these agreements on various components of net income (loss):

	Thr	Three Months Ended March 31,							
(In thousands)		2024	2023						
Revenues:									
Net premium earned	\$	10,770 \$	9,740						
Expenses:									
Loss and loss adjustment expenses incurred		6,681	6,249						
Policy acquisition costs		3,981	3,560						

The Company continues to be a party to various ceded reinsurance treaties with affiliates of Fairfax that were entered into in the ordinary course of business, primarily excess of loss reinsurance agreements with Odyssey Re for 2010 through 2024. As of March 31, 2024 and December 31, 2023, the Company recorded net receivables for reinsurance of \$0.1 million and \$0.4 million, respectively, related to the reinsurance transactions with affiliates of Fairfax. In the three months ended March 31, 2024 and 2023, the Company recorded 0.9 million of ceded premium earned net of ceded commissions related from the affiliates.

In the three months ended March 31, 2024 and 2023, Zenith National paid Fairfax \$2.1 million and \$0.1 million, respectively, for the cost of the open market purchases made by Fairfax on behalf of Zenith National of Fairfax Subordinate Voting Shares granted to certain officers under the Restricted Stock Plan.

The Company is party to Master Administrative Services Agreements with various affiliates of Fairfax and the Company. Under the agreements, the affiliated parties provide and receive administration services such as accounting, underwriting, claims, reinsurance, preparation of regulatory reports, and actuarial services. The Company provides claims administration services to Seneca Insurance Company, Inc. ("Seneca") and to RiverStone Group LLC and affiliates ("RiverStone"), both affiliates of Fairfax and the Company. In the three months ended March 31, 2024 and 2023, service fee income recorded in the Consolidated Statements of Comprehensive Income (Loss), for RiverStone was \$1.9 million and \$1.8 million, respectively, and for Seneca was \$11,000 and \$26,000, respectively. As of March 31, 2024 and December 31, 2023, the Company recorded a net liability of \$5.3 million and \$4.2 million, respectively, to RiverStone comprised of a loss fund held for RiverStone claims of \$5.9 million and \$4.6 million, respectively, offset by service fee receivables from RiverStone of \$0.5 million and \$0.4 million, respectively. As of March 31, 2024 and December 31, 2023, the loss fund held for Seneca claims was \$0.4 million.

Note 6. Reinsurance Recoverable

Amounts recoverable for paid and unpaid losses from reinsurers as of March 31, 2024 and December 31, 2023, and their respective A.M. Best ratings were as follows:

	March 31,	December 31,	A.M. Best	A.M. Best
(In thousands)	2024 (a)	2023 (a)	Rating (b)	Rating Date
General Reinsurance Company	\$ 20,874	20,137	A++	04-2023
Hannover Rueck SE	6,752	5,383	A+	12-2023
Partner Reinsurance Company	6,739	5,302	A+	02-2024
Transatlantic Reinsurance Company	5,784	5,934	A++	01-2024
Zenith Insurance 2019 California AG IC 1 LLC	2,689	2,401	NR	
Factory Mutual Insurance Company	2,116	1,779	A+	01-2024
Axis Reinsurance Company	1,968	1,703	Α	09-2023
Odyssey America Reinsurance Corp	1,525	1,340	A+	07-2023
Renaissance Reinsurance US Inc	1,386	1,263	A+	09-2023
Chaucer Ins Co Designated Activity Co	1,333	1,195	A+	11-2023
All others (c)	2,805	3,104		
Total	\$ 53,971 \$	49,541		

⁽a) Under insurance regulations in California, reinsurers placed securities on deposit equal to the California component of the Company's ceded workers' compensation loss reserves.

Note 7. Unpaid Losses and Loss Adjustment Expenses

The following table represents a reconciliation of changes in the liability for unpaid losses and loss adjustment expenses:

	Three Months Ended March 31,		
(In thousands)		2024	2023
Beginning of period, net of reinsurance	\$	999,781 \$	1,010,651
Incurred claims:			
Current accident year		112,412	113,772
Prior accident years		(11,326)	(11,262)
Total incurred claims		101,086	102,510
Payments:			_
Current accident year		(16,815)	(15,890)
Prior accident years		(85,569)	(92,288)
Total payments		(102,384)	(108,178)
End of period, net of reinsurance		998,483	1,004,983
Receivable from reinsurers for unpaid losses		45,159	39,621
End of period, gross of reinsurance	\$	1,043,642 \$	1,044,604

⁽b) A.M. Best, in assigning ratings, is primarily concerned with the ability of insurance and reinsurance companies to pay the claims of policyholders. In the A.M. Best ratings scheme, ratings of B+ to A++ are considered "Secure" and ratings of B and below are considered "Vulnerable." NR means A.M. Best does not rate the reinsurer.

⁽c) No individual reinsurer in excess of \$1.2 million as of March 31, 2024 and December 31, 2023.

Note 8. Stock-Based Compensation

The following table provides information regarding the Fairfax Subordinate Voting Shares under the Restricted Stock Plan:

	Number of Shares
Authorized for purchases and grants at plan inception in 2010	200,000
Additional authorization in 2020	300,000
Total authorized for purchases and grants	500,000
Purchased and restricted	(58,091)
Vested	(105,754)
Purchased and available for future grants	(3,339)
Available for future purchases as of March 31, 2024	332,816

The following represents open market purchases of Fairfax Subordinate Voting Shares under the Restricted Stock Plan which also resulted in charges to the Company's Stockholders' equity:

		Weighted Average	
	Number of	Purchase Price	Total
(Dollars in thousands, except share data)	Shares	Per Share	Purchase Price
Purchased through December 31, 2021	144,396	\$ 436.59	\$ 63,042
Purchased in 2022	18,290	509.21	9,313
Purchased in 2023	2,425	872.64	2,116
Purchased in 2024	2,073	1,014.30	2,102
Total purchased since plan inception	167,184	458.02	\$ 76,573

Changes in the restricted shares outstanding were as follows:

		Weighted	
		Average Grant	
	Number of	Date Fair Value	Grant
(Dollars in thousands, except share data)	Shares	Per Share	Date Fair Value
Restricted Shares as of December 31, 2021	69,940 \$	446.45	\$ 31,225
Granted during 2022	11,893	494.64	5,883
Forfeited during 2022	(1,905)	448.30	(854)
Vested during 2022	(14,211)	449.96	(6,394)
Restricted Shares as of December 31, 2022	65,717	454.36	29,860
Granted during 2023	8,420	514.35	4,331
Forfeited during 2023	(1,178)	452.36	(533)
Vested during 2023	(10,377)	506.66	(5,258)
Restricted Shares as of December 31, 2023	62,582	453.79	28,400
Granted during 2024	5,678	559.06	3,174
Vested during 2024	(10,169)	473.04	(4,810)
Restricted Shares as of March 31, 2024	58,091	460.71	\$ 26,764

In the three months ended March 31, 2024 and 2023, stock-based compensation expense before tax was \$1,5 million.

As of March 31, 2024 and December 31, 2023, unrecognized compensation expense before tax under the Restricted Stock Plan was \$14.2 million and \$12.5 million, respectively.

Note 9. Commitments and Contingencies

The Company is involved in various litigation proceedings that arise in the ordinary course of business. Disputes adjudicated in the workers' compensation administrative systems may be appealed to review boards or civil courts, depending on the issues and local jurisdictions involved. From time to time, plaintiffs also sue the Company on theories falling outside of the exclusive jurisdiction and remedies of the workers' compensation claims adjudication systems. Certain of these legal proceedings seek injunctive relief or substantial monetary damages, including claims for punitive damages, which may not be covered by reinsurance agreements. Historically, the Company has not experienced any material exposure or damages from any of these legal proceedings. In addition, in the opinion of management, after consultation with legal counsel, currently outstanding litigation is either without merit or the ultimate liability, if any, is not expected to have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.